2017 Preliminary Conference Program

Please note that events and times are subject to change.


Wednesday, September 6, 2017  

10:45 am - 11:00 am

Welcome

11:00 am - 12:30 pm

Session 1: Neoantigens

Ton Schumacher, The Netherlands Cancer Institute
T cell recognition of human cancer
Ugur Sahin, BioNTech Corp. Mainz, TRON Translational Oncology
Individualized cancer immunotherapy - exploring a new landscape
Stephen Schoenberger, La Jolla Institute

Lunch                                                                         12:30 pm - 1:30 pm

 1:30 pm - 3:30 pm

Session 1: Neoantigens continued

Catherine Wu, Dana-Farber Cancer Institute, Harvard Medical School
Building personal cancer vaccines
Sine Reker Hadrup, Technical University of Denmark
Detection of neoepitope reactive T cells based on personalized mutational landscapes
Timothy Chan, Memorial Sloan Kettering Cancer Center
Immunotherapy: What's genes got to do with it?
Proffered presentations to be selected from submitted abstracts

Refreshment Break                                                    3:30 pm - 4:00pm

 4:00 pm - 6:00 pm

Session 2: Novel mechanisms of immunosuppression and immune evasion

Nicholas Restifo, National Cancer Institute
Essential genes for cancer immunotherapy
Padmanee Sharma, The University of Texas MD Anderson Cancer Center
From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy
Jesse Zaretsky, UCLA Medical Center
Mechanisms of acquired resistance to anti - PD1 immunotherapy in melanoma
Proffered presentations to be selected from submitted abstracts

6:00 pm - 8:00 pm

Reception and Poster Session A


Thursday, September 7, 2017

8:00 am - 9:00 am

William B. Coley Lecture

Thomas Gajewski, The University of Chicago

Refreshment Break                                                   9:00 am - 9:30 am

Session 3: Tissue biomarkers predicting                9:30 am - 11:30 am
response to therapy 

Thomas Tüting, University Hospital Magdeburg
The role of neutrophils in cancer immunotherapy
Drew Pardoll, Johns Hopkins University
Wolf Hervé Fridman, Cordeliers Research Centre, University Paris - Descartes
Deleterious immune contextures in cancer

Proffered presentations to be selected from submitted abstracts

Lunch                                                                          11:30 pm - 1:00 pm

1:00 pm - 3:00 pm

Session 4: Novel agents

Ignacio Melero, Universidad de Navarra
Özlem Türeci, Ci3-Cluster for Individualized Immune Intervention
IMAB362 - A novel immune - effector activating mAB for the treatment of solid cancers
Patrick Baeuerle, TCR² Therapeutics Inc.
A novel approach to engineer T cells for solid tumor therapy engaging the complete T cell receptor
Proffered presentations to be selected from submitted abstracts

Refreshment Break                                                   3:00 pm - 3:30 pm

3:30 pm - 6:00 pm

Session 5: Adoptive cell therapies

Hyam Levitsky, Juno Therapeutics
Dirk Busch, Technical University Munich
Choice of optimal T cell subsets and implementation of sage guards for adoptive T cell therapy
Renier Brentjens, Memorial Sloan Kettering Cancer Center
Michael Jensen, University of Washington, School of Medicine, Department of Pediatrics
Next steps for iteration of CD19CAR therapy to definitive curative therapy
Proffered presentations to be selected from submitted abstracts


FRIDAY, September 8, 2017

8:00 am - 10:00 am

Session 6:  Combination therapies

Ira Mellman, Genentech
The mechanistic basis of cancer immunotheraphy
Sjoerd van der Burg, Department of Medical Oncology, Leiden University Medical Center
Myeloid cell modulating chemotherapy and therapeutic vaccination for treatment of HPV - driven cancers
Alexander Eggermont, Gustave Roussy Cancer Institute
The IO revolution: what to learn from melanoma
Proffered presentations to be selected from submitted abstracts

Refreshment Break                                                  10:00 am - 10:30 am

10:30 am - 12:30 pm

Session 7:  Novel approaches for checkpoint blockade failure

George Coukos, Ludwig Institute for Cancer Research
Alexander Rudensky, Memorial Sloan Kettering Cancer Center
Regulatory T cell function in health and disease
Sergio Quezada, University College London Cancer Institute
Targeting regulation at the tumor site
Proffered presentations to be selected from submitted abstracts

Lunch                                                                        12:30 pm - 2:00 pm

Session 8:  Microbiota                                              2:00 pm - 3:15 pm

Laurence Zitvogel, Gustave Roussy Cancer Institute
Giorgio Trinchieri, National Institutes of Health
Microbiota and cancer
Proffered presentations to be selected from submitted abstracts

Refreshment Break                                                   3:30 pm - 4:00 pm

Session 9:  Other checkpoint blocking and           4:00 pm - 5:30 pm
immunomodulating antibodies 

Charles Drake, Columbia University Medical Center
Treg depletion as a foundation for combinatorial Immunotherapy
Ana Anderson, Harvard Medical School
Regulation of the CD8+ T cell response in cancer
Martin Glennie, University of Southampton                                        

Keynote Lecture                                                         5:30 pm - 6:15 pm

Alberto Mantovani, Instituto Clinico Humanitas, Humanitas University
The yin - yang of innate immunity, inflammation and cancer

Reception and Poster Session B                               6:15 pm - 8:30 pm


Saturday, September 9, 2017

8:00 am - 10:00 am

Session 10: Therapy against hostile elements in the cancer microenvironment

Dmitry Gabrilovich, The Wistar Institute
Therapeutic regulation of myeloid - derived suppressor cells
Serge Fuchs, University of Pennsylvania
Inactivation of type I interferon signaling in tumor microenvironment: therapeutic implications
Yousef Zahkaria, University of Iowa
IDO inhibitor in melanoma
Proffered presentations to be selected from submitted Abstracts.

Refreshment Break                                                   10:00 am - 10:30 am

10:30 am - 12:15 pm

Session 11: Oncolytic viruses

John Bell, Ottawa Hospital Research Institute
Replicating viruses as biological machines to treat cancer
Pedro Beltran, Amgen Inc.
Mechanisms of action of talimogene laherparepvec: From bench to bedside
Stephen J. Russell, Mayo Clinic
Proffered presentations to be selected from submitted abstracts